Elkayam O - Search Results

1

Prevalence of COVID-19 and seroprevalence to SARS-CoV-2 in a rheumatologic patient population from a tertiary referral clinic in Israel.

Eviatar T, Elalouf O, Furer V, Goldstein-Lahat Y, Paran Y, Pel S, Nevo S, Zisapel M, Alcalay Y, Elkayam O. Eviatar T, et al. Among authors: elkayam o. Intern Med J. 2021 May;51(5):682-690. doi: 10.1111/imj.15202. Epub 2021 May 12. Intern Med J. 2021. PMID: 33844415 Free PMC article.

2

INFLAMET: an image analyzer to display erythrocyte adhesiveness/aggregation.

Fusman R, Zeltser D, Rotstein R, Chapman J, Avitzour D, Shapira I I, Eldor A, Elkayam O, Caspi D, Arber N, Berliner S. Fusman R, et al. Among authors: elkayam o. Eur J Intern Med. 2000 Oct;11(5):271-276. doi: 10.1016/s0953-6205(00)00108-4. Eur J Intern Med. 2000. PMID: 11025252

3

Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis.

Zisapel M, Zisman D, Madar-Balakirski N, Arad U, Padova H, Matz H, Maman-Sarvagyl H, Kaufman I, Paran D, Feld J, Litinsky I, Wigler I, Caspi D, Elkayam O. Zisapel M, et al. Among authors: elkayam o. J Rheumatol. 2015 Jan;42(1):73-8. doi: 10.3899/jrheum.140685. Epub 2014 Nov 15. J Rheumatol. 2015. PMID: 25399390

4

Decreased diffusion capacity on lung function testing in asymptomatic patients with systemic lupus erythematosus does not predict future lung disease.

Elalouf O, Fireman E, Levartovsky D, Kaufman I, Rogovski O, Elkayam O, Caspi D, Paran D. Elalouf O, et al. Among authors: elkayam o. Lupus. 2015 Aug;24(9):973-9. doi: 10.1177/0961203314566633. Epub 2015 Jan 16. Lupus. 2015. PMID: 25595620

5

Systemic lupus erythematosus exacerbation following cessation of belimumab treatment.

Furer V, Zisman D, Pokroy-Shapira E, Molad Y, Elkayam O, Paran D. Furer V, et al. Among authors: elkayam o. Scand J Rheumatol. 2016;45(2):103-6. doi: 10.3109/03009742.2015.1074277. Epub 2015 Oct 29. Scand J Rheumatol. 2016. PMID: 26515057

6

Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis.

Elalouf O, Elkayam O. Elalouf O, et al. Among authors: elkayam o. Ther Clin Risk Manag. 2015 Nov 19;11:1719-26. doi: 10.2147/TCRM.S55928. eCollection 2015. Ther Clin Risk Manag. 2015. PMID: 26640380 Free PMC article. Review.

7

The Effect of the Presence of Fibromyalgia on Common Clinical Disease Activity Indices in Patients with Psoriatic Arthritis: A Cross-sectional Study.

Brikman S, Furer V, Wollman J, Borok S, Matz H, Polachek A, Elalouf O, Sharabi A, Kaufman I, Paran D, Elkayam O. Brikman S, et al. Among authors: elkayam o. J Rheumatol. 2016 Sep;43(9):1749-54. doi: 10.3899/jrheum.151491. Epub 2016 Jun 1. J Rheumatol. 2016. PMID: 27252430

8

Authors' reply.

Furer V, Zisman D, Pokroy-Shapira E, Molad Y, Elkayam O, Paran D. Furer V, et al. Among authors: elkayam o. Scand J Rheumatol. 2017 May;46(3):251-252. doi: 10.1080/03009742.2016.1264628. Epub 2017 Feb 16. Scand J Rheumatol. 2017. PMID: 28276956 No abstract available.

9

[PRECLINICAL RHEUMATOID ARTHRITIS].

Elalouf O, Elkayam O. Elalouf O, et al. Among authors: elkayam o. Harefuah. 2017 Jul;156(7):451-454. Harefuah. 2017. PMID: 28786276 Review. Hebrew.

10

Expression levels of selected genes can predict individual rheumatoid arthritis patient response to tumor necrosis factor alpha blocker treatment.

Paran D, Smith Y, Pundak S, Arad U, Levartovsky D, Kaufman I, Wollman J, Furer V, Broyde A, Elalouf O, Caspi D, Pel S, Elkayam O. Paran D, et al. Among authors: elkayam o. Curr Med Res Opin. 2018 Oct;34(10):1777-1783. doi: 10.1080/03007995.2018.1443581. Epub 2018 Mar 23. Curr Med Res Opin. 2018. PMID: 29569514

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

243 results

Search Page